{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-027717","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.567533+00:00","generated_at":"2026-05-26T04:11:17.697492+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M","bullets":["Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.","GAAP net income $159.0M ($1.50 diluted EPS); non-GAAP net income $206.0M ($1.90 EPS).","Full-year 2024 total revenues $1.9B (+53% YoY); GAAP net income $235.2M vs $536M net loss in 2023.","2025 net product revenue guidance $2.9B-$3.1B (70% YoY growth); ELEVIDYS expected to grow 162%.","Closed Arrowhead licensing deal for 4 clinical-stage siRNA programs; established $600M revolving credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-027717","json":"https://secwatch.observer/filing/0000950170-25-027717.json","markdown":"https://secwatch.observer/filing/0000950170-25-027717.md","text":"https://secwatch.observer/filing/0000950170-25-027717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017025027717/0000950170-25-027717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017025027717/srpt-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:11:17.697492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}